CTOs on the Move

Inozyme

www.inozyme.com

 
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inozyme.com
  • 321 Summer Street Suite 400
    Boston, MA USA 02210
  • Phone: 857.330.4340

Executives

Name Title Contact Details

Funding

Inozyme raised $49M on 11/15/2017

Similar Companies

Lacerta Therapeutics

Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases

MOMA Therapeutics

We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.

Nano Cures

The greatest health threats require more than an all-or-nothing approach. Nano represents a multi-layered set of solutions to usher in a new era in proactive, persistent health protection.

Nocion Therapeutics

NOCION is a biopharmaceutical company that is addressing vexing medical problems head on. We are developing `nocions`—a new kind of therapy that selectively affects actively firing nocioceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.